Biodesix vs Grail
BDSX and GRAL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDSX and GRAL compare
Grail is the larger company, worth 50 times as much as Biodesix ($4.7B against $95.0M).
Biodesix grew revenue faster over the last twelve months (34.5% versus 23.1% for Grail).
Biodesix keeps more of each dollar of sales as profit, with a net margin of −27.0% compared with −237% at Grail.
Grail scores higher on the StockData Score (10 against 4 for Biodesix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDSX | GRAL |
|---|---|---|
| Size and price | ||
| Market cap | $95.0M | $4.7B |
| Share price | $9.00 | $105.60 |
| Change, 1 year | 13.9% | 26.9% |
| Change, 5 years | −93.3% | – |
| Beta (5Y) | 1.71 | 2.06 |
| Employees | 334 | 910 |
| StockData Score | ||
| Total score | 4 | 10 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.9× (better) | 28.5× |
| P/B | 10.4× | 1.9× (better) |
| FCF yield | −21.3% | −6.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 34.5% (better) | 23.1% |
| Revenue growth, 5Y average | 14.2% | – |
| Profitability | ||
| Operating margin | −20.0% (better) | −338% |
| Net margin | −27.0% (better) | −237% |
| FCF margin | −19.7% (better) | −179% |
| Return on equity | −540% | −16.1% (better) |
| Return on invested capital | −61.4% | −26.0% (better) |
| Financial health | ||
| Debt / equity | 5.12 (better) | 0.00 |
| Interest coverage | −2.5× | – |
| Current ratio | 2.85 | 10.95 (better) |
| Altman Z-score | −6.15 | 4.03 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 41.4% | 87.6% |
| Held by insiders | – | 11.0% |
| Insider net buying, 12 months | $4.0M (better) | −$38.0M |
| Short interest, % of float | – | 20.1% |
Go deeper
- BDSX stock overview
- BDSX income statement
- BDSX valuation and score
- GRAL stock overview
- GRAL income statement
- GRAL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.